[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020

January 2020 | 99 pages | ID: C1B2CBA2467EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 3, 8, 1, 11, 3 and 3 respectively.

Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Chemotherapy Induced Nausea and Vomiting - Overview
Chemotherapy Induced Nausea and Vomiting - Therapeutics Development
Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
Chemotherapy Induced Nausea and Vomiting - Drug Profiles
Chemotherapy Induced Nausea and Vomiting - Dormant Projects
Chemotherapy Induced Nausea and Vomiting - Discontinued Products
Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by AcuCort AB, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Amzell BV, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Artelo Biosciences Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Axim Biotechnologies Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Bod Australia Ltd, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Ci Therapeutics, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Emerald Bioscience Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Ethicann Pharmaceuticals Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Group, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Hoverink Biotechnologies Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Huons Co Ltd, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by IntelGenx Corp, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by LipoSeuticals Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Luxena Pharmaceuticals Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Maxinase Life Sciences Ltd, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Nevakar Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Pivot Pharmaceuticals Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Serina Therapeutics Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Starton Therapeutics Inc, H1 2020
Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Pharmaceuticals Ltd, H1 2020
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2020
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2020 (Contd..1), H1 2020
Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H1 2020

LIST OF FIGURES

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Acacia Pharma Ltd
AcuCort AB
Amzell BV
Aphios Corp
Artelo Biosciences Inc
Athenex Inc
Axim Biotechnologies Inc
Bod Australia Ltd
Camurus AB
Ci Therapeutics
Daewoong Pharmaceutical Co Ltd
Emerald Bioscience Inc
Ethicann Pharmaceuticals Inc
Helsinn Group
Hoverink Biotechnologies Inc
Huons Co Ltd
IntelGenx Corp
LipoSeuticals Inc
Luxena Pharmaceuticals Inc
MannKind Corp
Maxinase Life Sciences Ltd
Nevakar Inc
Pivot Pharmaceuticals Inc
Serina Therapeutics Inc
SoluBest Ltd
Starton Therapeutics Inc
Suda Pharmaceuticals Ltd


More Publications